Category: Active Surveillance

“It has been suggested by some investigators that a negative or stable MRI could replace the surveillance biopsy in men on AS.” – Dr. Badar Mian With apologies to Ralph Waldo Emerson for paraphrasing a famous saying attributed to him: Build a better prostate biopsy and the urological world will beat a path to your keep reading

I just read a terrific blog by a Chicago author, Howard Wolinsky, who has been on Active Surveillance for Wilensky 10 years. He has Gleason 3+3 prostate cancer—and is doing just fine! As he reflects on his own experience, he quotes from several experts in urologic surgery and clinical pathology. Spoiler alert: he articulates both keep reading

The average male human heart is slightly less than a half percent of total body weight, and it weighs about ten times more than the same man’s prostate gland. Most people would likely agree that the heart is at least ten times more important than the prostate. However, I suspect that the average man thinks keep reading

At first glance, the title question appears to have a self-evident answer. Everyone knows that a good workout program that includes at least 150 minutes of aerobic exercise is advantageous for the body’s cardiovascular system. This increases the chance of a long life in good health. And of course, we’re all aware that aerobic fitness keep reading

Who is the world’s leading prostate cancer expert? How does one even begin to answer that question? There are so many great minds dealing with prostate cancer from so many angles: biology, urology, radiology, oncology, pathology and more—it’s impossible to identify a single authority on the subject. However, when great minds work together, powerful consensus keep reading

In recent years, there’s been a huge groundswell of Active Surveillance (AS) for low-risk prostate cancer (PCa) patients. In fact, it’s considered the preferred PCa management strategy for men with lower-risk disease. There are two primary factors at play: 1) patient resistance to undergoing definitive whole gland treatments that can impair urinary and sexual function, keep reading

“Despite increasing adoption of active surveillance (AS) for low-risk prostate cancer, AS discontinuation rates are high, investigators report.” This quote, from a September 2021 Renal & Urology News report, referred to a study of over 16,000 Canadian prostate cancer (PCa) patients who had been diagnosed with low risk disease from 2008-2014. 51% of these patients keep reading

In recent years, there’s been a huge shift in understanding the difference between insignificant and significant prostate cancer (PCa). Over 15 years ago, Albertsen, et al. (2005) established that clinically insignificant PCa could be defined as cancer that “will not affect the patient during the natural course of his lifetime. The indolent course of localised keep reading

Fourteen months prior to the time of this writing, the world began locking down due to the emerging SARS-CoV-2 viral pandemic and the potentially deadly COVID illness it causes. We were all confused, and studies repeatedly show that normal screening for cancers such as breast, prostate and colorectal dropped significantly... keep reading

Good news! The widespread integration of multiparametric MRI (mpMRI) and MRI-guided targeted biopsies has resulted in both better initial qualification of AS candidates, and significantly better ability to monitor for significant PCa by PSA + mpMRI. As a side benefit... keep reading